
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>American College of Gastroenterology Guidelines:
Management of Acute Pancreatitis</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 25px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>American College of Gastroenterology Guidelines:</strong><br><em>Management of Acute Pancreatitis</em></summary>
            <div>
                <ul><li>Am J Gastroenterol 2024;119:419–437.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What is the recommended initial fluid resuscitation rate for patients with acute pancreatitis who show no evidence of hypovolemia?</li><li>2. In patients with idiopathic acute pancreatitis, what is the number needed to treat with cholecystectomy to prevent one recurrent attack?</li><li>3. What is the single dose of rectal indomethacin recommended to prevent post-ERCP pancreatitis in high-risk patients?</li><li>4. What is the definition of pancreatic necrosis in terms of size or percentage of the pancreas involved?</li><li>5. What is the preferred route for delivering enteral feeding in patients with moderately severe or severe acute pancreatitis?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis of Acute Pancreatitis</strong></summary>
            <div>
                <ul><li>Diagnosis is established by identifying <b>2 of the following 3 criteria</b>.</li></ul>
                
        <details>
            <summary><strong>Diagnostic Criteria</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Abdominal Pain</strong></summary>
            <div>
                <ul><li>Typically epigastric or left upper quadrant, constant, with radiation to the back, chest, or flanks.</li><li>Pain described as dull, colicky, or in the lower abdomen is <u>not consistent</u> with AP.</li><li>Intensity and location of pain <u>do not correlate</u> with severity.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Serum Enzymes</strong></summary>
            <div>
                <ul><li>Serum amylase and/or lipase greater than <q><b>3 times</b></q> the upper limit of normal.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Imaging Findings</strong></summary>
            <div>
                <ul><li>Characteristic findings from abdominal imaging (e.g., CT, MRI).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Laboratory Evaluation</strong></summary>
            <div>
                <ul><li>Once the diagnosis is established, there is <u>no reason to serially follow</u> serum amylase or lipase levels.</li></ul>
                
        <details>
            <summary><strong>Serum Lipase</strong></summary>
            <div>
                <ul><li><u>Preferred over amylase</u> for diagnosis.</li><li>More specific and remains elevated longer than amylase.</li><li>In some patient groups (e.g., diabetics), a cutoff of > <q><b>3-5 times</b></q> the upper limit of normal may be needed.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Serum Amylase</strong></summary>
            <div>
                <ul><li>Rises within hours of onset and returns to normal within <q><b>3–5 days</b></q>.</li><li>May be within the normal range on admission in as many as <q><u>one-fifth of patients</u></q>.</li><li>Can be normal in alcohol-induced AP and hypertriglyceridemia.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Role of Imaging in Diagnosis</strong></summary>
            <div>
                <ul><li><u>Routine early CT is not recommended</u> for diagnosis or severity assessment.</li></ul>
                
        <details>
            <summary><strong>Indications for Imaging</strong></summary>
            <div>
                <ul><li>Reserved for patients where the diagnosis is unclear.</li><li>Recommended for patients who fail to improve clinically within the first <q><b>48–72 hours</b></q> to assess for local complications.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Computed Tomography (CT)</strong></summary>
            <div>
                <ul><li>Contrast-enhanced CT provides > <q><b>90%</b></q> sensitivity and specificity for diagnosis.</li><li>Newer techniques like perfusion CT may detect necrosis earlier.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Magnetic Resonance Imaging (MRI)</strong></summary>
            <div>
                <ul><li>Comparable to CT for early assessment.</li><li>Advantages in patients with contrast allergy or renal insufficiency.</li><li>More accurate for detecting stones in the common bile duct (CBD) and pancreatic duct disruption.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Etiology of Acute Pancreatitis</strong></summary>
            <div>
                <ul><li>The cause of AP can be established in most patients through initial evaluation.</li></ul>
                
        <details>
            <summary><strong>Common Causes</strong></summary>
            <div>
                
                
        <details>
            <summary><strong><b>Gallstones</b></strong></summary>
            <div>
                <ul><li>Most common cause, accounting for <q><b>40%–70%</b></q> of cases.</li><li><u>Transabdominal ultrasound</u> should be performed on all patients with AP.</li><li>If the initial ultrasound is inconclusive, a repeat study is suggested.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong><b>Alcohol</b></strong></summary>
            <div>
                <ul><li>Second most common cause, accounting for <q><b>25%–35%</b></q> of cases.</li><li>Diagnosis requires a history of > <q><b>5 years</b></q> of moderate or heavy alcohol consumption (> 50 g per day).</li><li>Only up to <q><u>5% of heavy drinkers</u></q> develop clinically evident AP, suggesting other cofactors like genetics and tobacco use.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Other Etiologies</strong></summary>
            <div>
                <ul><li>Caution must be exercised when attributing AP to rarer causes.</li></ul>
                
        <details>
            <summary><strong>Hypertriglyceridemia</strong></summary>
            <div>
                <ul><li>Accounts for up to <q><b>5%</b></q> of all AP cases, and up to <q><b>56%</b></q> of AP in pregnancy.</li><li>Serum triglyceride level should be > <q><b>1,000 mg/dL</b></q> to be considered the cause.</li><li>The risk of AP increases by <q><u>4% for every 100 mg/dL</u></q> of TG above the normal limit.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pancreatic Tumors</strong></summary>
            <div>
                <ul><li>Should be suspected in any patient > <q><b>40 years old</b></q> with idiopathic pancreatitis.</li><li>Approximately <q><b>1%</b></q> of AP cases are due to pancreatic cancer.</li><li>Requires evaluation with contrast-enhanced CT or MRI/MRCP.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Medications</strong></summary>
            <div>
                <ul><li>A rare cause of AP.</li><li>Drugs with a clear association include <b>6-mercaptopurine, azathioprine, and didanosine</b>.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Idiopathic and Recurrent AP</strong></summary>
            <div>
                <ul><li>Recurrent AP occurs in approximately <q><b>20%–29%</b></q> of patients after an initial attack.</li></ul>
                
        <details>
            <summary><strong>Diagnostic Evaluation</strong></summary>
            <div>
                <ul><li>For idiopathic AP (IAP), additional evaluation with repeat ultrasound, MRI, and/or endoscopic ultrasound (EUS) is suggested.</li><li>EUS can identify an etiology in <q><u>almost a third</u></q> of patients after an initial attack of IAP.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Role of Cholecystectomy in IAP</strong></summary>
            <div>
                <ul><li>Gallstones or microlithiasis are often the underlying cause of IAP.</li><li>Following a second episode of AP with no identifiable cause, cholecystectomy is suggested to reduce recurrence.</li><li>The number needed to treat to prevent one attack is <q><b>5</b></q>.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Initial Assessment & Risk Stratification</strong></summary>
            <div>
                <ul><li>Early risk assessment is crucial to triage patients to the appropriate level of care.</li></ul>
                
        <details>
            <summary><strong>Severity Classification (Revised Atlanta)</strong></summary>
            <div>
                
                
        <details>
            <summary><strong><b>Mild AP</b></strong></summary>
            <div>
                <ul><li>Absence of organ failure and local or systemic complications.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong><b>Moderately Severe AP</b></strong></summary>
            <div>
                <ul><li>Characterized by transient organ failure (resolves within <q><b>48 hours</b></q>) and/or the presence of local complications (e.g., fluid collections, necrosis).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong><b>Severe AP</b></strong></summary>
            <div>
                <ul><li>Defined by the presence of <u>persistent organ failure</u> (fails to resolve within <q><b>48 hours</b></q>).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Morphologic Classification</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Interstitial Edematous Pancreatitis</strong></summary>
            <div>
                <ul><li>Corresponds to mild disease, characterized by pancreatic edema.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Necrotizing Pancreatitis</strong></summary>
            <div>
                <ul><li>Defined as diffuse or focal areas of nonviable pancreatic parenchyma > <q><b>3 cm</b></q> in size or > <q><b>30%</b></q> of the pancreas.</li><li>Includes peripancreatic necrosis (<q>~45%</q>), combined pancreatic and peripancreatic necrosis (<q>~45%</q>), and pure pancreatic necrosis (<q>~5%</q>).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Predicting Severe Disease</strong></summary>
            <div>
                <ul><li>Scoring systems (Ranson, APACHE) are cumbersome and often inaccurate in the first 48 hours.</li><li><u>Expert clinician judgment</u> and simple markers are often as effective.</li></ul>
                
        <details>
            <summary><strong>Key Risk Factors for Severe Disease</strong></summary>
            <div>
                <ul><li><b>Patient characteristics:</b> Age > 55, Obesity (BMI > 30), altered mental status, comorbidities.</li><li><b>Laboratory findings:</b> BUN > 20 mg/dL, rising BUN, HCT > 44%, rising HCT, elevated creatinine.</li><li><b>Radiology findings:</b> Pleural effusions, pulmonary infiltrates.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Systemic Inflammatory Response Syndrome (SIRS)</strong></summary>
            <div>
                <ul><li>Defined by the presence of <b>≥2</b> of the following: Pulse > 90, Respirations > 20, Temp > 38°C or < 36°C, WBC > 12,000 or < 4,000.</li><li>Presence of SIRS at admission is highly predictive of developing organ failure.</li><li>SIRS has a sensitivity of <q><b>85%</b></q> for predicting organ failure and <q><b>100%</b></q> for mortality, but lacks specificity.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Triage and Monitoring</strong></summary>
            <div>
                <ul><li>Patients with organ failure and/or SIRS should be admitted to a <u>monitored bed setting or ICU</u>.</li><li>Clinicians should remain vigilant for deterioration during the initial <q><b>48 hours</b></q>, even in patients with seemingly mild disease.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Initial Management: Fluid Resuscitation</strong></summary>
            <div>
                <ul><li>Intravenous hydration is the cornerstone of initial treatment for AP.</li></ul>
                
        <details>
            <summary><strong>Fluid Type</strong></summary>
            <div>
                <ul><li>We suggest using <u><b>Lactated Ringer's solution</b></u> over normal saline.</li></ul>
                
        <details>
            <summary><strong>Benefits of Lactated Ringer's</strong></summary>
            <div>
                <ul><li>Reduces systemic inflammation compared to saline.</li><li>More pH-balanced, avoiding the non-anion gap hyperchloremic metabolic acidosis associated with large volumes of normal saline.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Fluid Rate and Volume</strong></summary>
            <div>
                <ul><li>We suggest <b>moderately aggressive</b> fluid resuscitation, especially within the first <q><b>24 hours</b></q>.</li></ul>
                
        <details>
            <summary><strong>Recommended Rates</strong></summary>
            <div>
                <ul><li>In patients with no evidence of hypovolemia, an initial rate of no more than <q><b>1.5 mL/kg/hr</b></q> should be administered.</li><li>In patients with hypovolemia, a bolus of <q><b>10 mL/kg</b></q> should be given.</li><li>Most patients will likely benefit from <q><b>3–4 Liters</b></q> in the first 24 hours.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cautions</strong></summary>
            <div>
                <ul><li>Aggressive hydration beyond 48 hours or in patients with established severe disease may be harmful.</li><li>Caution is needed in older patients and those with cardiovascular or renal comorbidities.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Monitoring Resuscitation</strong></summary>
            <div>
                <ul><li>Fluid volumes need to be reassessed at frequent intervals, starting within <q><b>6 hours</b></q> of presentation.</li></ul>
                
        <details>
            <summary><strong>Goals of Therapy</strong></summary>
            <div>
                <ul><li>The primary goal is to <u>decrease the BUN</u>.</li><li>A decrease in HCT (hemodilution) is also associated with better outcomes.</li><li>Monitor for signs of volume overload, such as pulmonary edema.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Role of ERCP in Acute Pancreatitis</strong></summary>
            <div>
                <ul><li>The role of ERCP is limited and depends on the clinical context.</li></ul>
                
        <details>
            <summary><strong>Acute Biliary Pancreatitis <b>with Cholangitis</b></strong></summary>
            <div>
                <ul><li>In patients with AP complicated by cholangitis, <u>early ERCP</u> (within the first <q><b>24 hours</b></q>) is recommended.</li><li>This has been shown to decrease morbidity and mortality.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Acute Biliary Pancreatitis <b>without Cholangitis</b></strong></summary>
            <div>
                <ul><li>We suggest <u>medical therapy over early ERCP</u> (within the first 72 hours).</li><li>Most CBD stones pass spontaneously, and early ERCP in this setting does not reduce complications or mortality.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Screening for CBD Stones</strong></summary>
            <div>
                <ul><li>In the absence of cholangitis or jaundice, if a CBD stone is suspected, <b>MRCP or EUS</b> should be used for screening.</li><li><u>Diagnostic ERCP should be avoided</u> to prevent unnecessary risk.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Preventing Post-ERCP Pancreatitis (PEP)</strong></summary>
            <div>
                <ul><li>AP is the most common complication of ERCP, with an incidence of <q><b>1%–30%</b></q>.</li></ul>
                
        <details>
            <summary><strong>Pharmacologic Prophylaxis</strong></summary>
            <div>
                <ul><li>We recommend <b>rectal indomethacin</b> to prevent PEP in high-risk individuals.</li><li>The standard dose is a single <q><b>100 mg</b></q> suppository given before or immediately after ERCP.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Mechanical Prophylaxis</strong></summary>
            <div>
                <ul><li>We suggest placement of a <b>pancreatic duct stent</b> in patients at high risk for PEP who are also receiving rectal indomethacin.</li><li>Combination therapy is superior to indomethacin alone in high-risk patients at centers of expertise.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Periprocedural Hydration</strong></summary>
            <div>
                <ul><li>Periprocedcedural hydration with <b>Lactated Ringer's solution</b> has been shown to prevent PEP.</li><li>One effective protocol is <q><b>3 mL/kg/hr</b></q> during ERCP, a <q><b>20 mL/kg</b></q> bolus after, followed by an 8-hour infusion at <q><b>3 mL/kg/hr</b></q>.</li><li>Ongoing aggressive hydration post-ERCP may not be effective if rectal indomethacin is also used.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>The Role of Antibiotics in AP</strong></summary>
            <div>
                <ul><li>The use of antibiotics is controversial and depends on the clinical scenario.</li></ul>
                
        <details>
            <summary><strong>Prophylactic Use in <b>Sterile Necrosis</b></strong></summary>
            <div>
                <ul><li>We suggest <u>against</u> prophylactic antibiotics in patients with severe AP and sterile necrosis.</li><li>Multiple well-designed, placebo-controlled trials have failed to show a benefit in reducing mortality or infection of necrosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment of <b>Infected Necrosis</b></strong></summary>
            <div>
                <ul><li>Antibiotics are a key part of treatment for infected necrosis, along with eventual debridement/necrosectomy.</li><li>Antibiotics are often used to <u>delay intervention</u> beyond <q><b>4 weeks</b></q> to allow the collection to mature.</li><li>Some patients may resolve the infection with antibiotics alone and avoid drainage.</li></ul>
                
        <details>
            <summary><strong>Choice of Antibiotics</strong></summary>
            <div>
                <ul><li>Antibiotics known to penetrate pancreatic necrosis should be used.</li><li>Examples include: <b>carbapenems, quinolones, cephalosporins, and metronidazole</b>.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Role of CT-Guided Fine-Needle Aspiration (FNA)</strong></summary>
            <div>
                <ul><li>We suggest <u>against</u> routine FNA in patients with suspected infected pancreatic necrosis.</li><li>Management decisions are often not influenced by FNA results, as antibiotics are often started on clinical suspicion alone.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Antifungal Agents</strong></summary>
            <div>
                <ul><li><u>Routine administration</u> of antifungal agents along with antibiotics is <u>not needed</u>.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Nutrition in AP</strong></summary>
            <div>
                <ul><li>Nutritional strategy has shifted from 'gut resting' to 'gut rousing' to maintain mucosal integrity and prevent bacterial translocation.</li></ul>
                
        <details>
            <summary><strong>Nutrition in <b>Mild AP</b></strong></summary>
            <div>
                <ul><li>We suggest <b>early oral feeding</b> (within <q><b>24–48 hours</b></q>) as tolerated.</li><li>This approach reduces hospital stay and costs.</li></ul>
                
        <details>
            <summary><strong>Diet Type</strong></summary>
            <div>
                <ul><li>We suggest initiating feeding with a <b>low-fat solid diet</b>.</li><li>A stepwise approach from clear liquids to solids is <u>not necessary</u> and provides fewer calories.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Nutrition in <b>Moderately Severe & Severe AP</b></strong></summary>
            <div>
                <ul><li>Enteral nutrition is preferred to prevent infectious complications by maintaining the gut barrier.</li></ul>
                
        <details>
            <summary><strong>Enteral vs. Parenteral</strong></summary>
            <div>
                <ul><li><b>Enteral nutrition</b> is superior to Total Parenteral Nutrition (TPN).</li><li>TPN is associated with more infectious and line-related complications and should be avoided unless the enteral route is not feasible.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Route of Enteral Feeding</strong></summary>
            <div>
                <ul><li>A <b>nasogastric</b> route is preferred over a nasojejunal route.</li><li>Nasogastric feeding is comparable in safety and efficacy, and tube placement is easier and less expensive.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Timing of Enteral Feeding</strong></summary>
            <div>
                <ul><li>The timing is controversial.</li><li>A large randomized trial found that early enteral feeding (within <q><b>24 hours</b></q>) did <u>not</u> reduce infection rates or mortality compared to on-demand feeding.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>The Role of Surgery in AP</strong></summary>
            <div>
                <ul><li>Surgical management has evolved significantly, favoring delayed and minimally invasive approaches.</li></ul>
                
        <details>
            <summary><strong>Cholecystectomy for Biliary Pancreatitis</strong></summary>
            <div>
                <ul><li>In patients with <b>mild gallstone pancreatitis</b>, cholecystectomy should be performed early, preferably <u>during the same hospital admission</u>.</li><li>This reduces recurrent biliary events (readmission rate of <q><b>18%</b></q> in delayed group vs 0% in early group) and is cost-effective.</li><li>In patients with necrosis, cholecystectomy is typically delayed.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Management of Pancreatic Necrosis</strong></summary>
            <div>
                <ul><li>The approach to necrosis has shifted from early, aggressive surgery to a more conservative, delayed strategy.</li></ul>
                
        <details>
            <summary><strong>Timing of Intervention</strong></summary>
            <div>
                <ul><li>We suggest <u>delaying any intervention</u> (surgical, radiological, endoscopic) in stable patients with pancreatic necrosis.</li><li>The preferred delay is <q><b>> 4 weeks</b></q> to allow for the wall of the collection to mature (walled-off necrosis).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Infected Necrosis Management</strong></summary>
            <div>
                <ul><li>Urgent surgery is no longer considered mandatory for all patients with infected necrosis.</li><li>Initial management for stable patients is a <q><b>2- to 4-week</b></q> course of antibiotics.</li><li>Delaying necrosectomy until <q><b>> 30 days</b></q> after admission is associated with decreased mortality.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Minimally Invasive Approaches</strong></summary>
            <div>
                <ul><li>Minimally invasive methods are <u>preferred</u> to open surgery for necrosectomy in stable patients.</li><li>These methods include percutaneous drainage, video-assisted retroperitoneal debridement (VARD), and endoscopic necrosectomy.</li></ul>
                
        <details>
            <summary><strong>Step-Up Approach</strong></summary>
            <div>
                <ul><li>A step-up approach (e.g., percutaneous catheter drainage followed by VARD) has shown lower morbidity and costs compared to open surgery.</li><li>Percutaneous drainage alone is successful in avoiding surgery in approximately <q><b>50%</b></q> of cases.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Necrosectomy</strong></summary>
            <div>
                <ul><li>Involves creating a transluminal opening (e.g., through the stomach) to remove necrotic tissue.</li><li>One randomized trial found endoscopic necrosectomy to be <u>superior to surgical necrosectomy</u>.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
